Vaccinex

Company snapshot

Vaccinex (NASDAQ: VCNX) is a clinical stage biotechnology company pioneering a differentiated approach to treating cancer and progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers damaging inflammation in

• 11 active pipeline program(s) linked via ClinicalTrials.gov.
• 41 US patent(s) indexed to this assignee profile.
• 11 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Vaccinex. Not investment advice.

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  Merck KGaA, Darmstadt

  TA overlap score 32.6

• Peer + 0 momentum

  Serana Europe

  TA overlap score 21.6

Recent activity

Latest pipeline, patent, and corporate events for Vaccinex.

1. Jun 8, 2026 Clinical update

   Anti-SEMA4D Monoclonal Antibody VX15/2503 — Phase 1

2. Jun 8, 2026 Clinical update

   Anti-SEMA4D Monoclonal Antibody VX15/2503 — Phase 1

3. Jun 5, 2026 Clinical update

   Dendritic Cell (DC1) Vaccine — Phase 1

4. May 23, 2026 Clinical update

   Avelumab and Pepinemab — Phase 2

5. May 23, 2026 Clinical update

   VX15/2503 — Phase 2

View all clinical trial activity →

• What is Vaccinex?

  Vaccinex is a pharma organization headquartered in Rochester, USA. It trades on NYSE under ticker VCNX. Primary therapeutic focus areas include Colon Carcinoma Metastatic in the Liver, Metastatic Melanoma, Metastatic Pancreatic Adenocarcinoma, HER2-positive Breast Cancer, Patholo

• Is Vaccinex publicly traded?

  Yes. Vaccinex is listed with ticker VCNX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Vaccinex develop or market?

  We link 8 drug profile(s) where Vaccinex is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/vaccinex-inc#company-drugs.

• What are the latest developments for Vaccinex?

  In the last 12 months our linked public records show 11 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Vaccinex focus on?

  Vaccinex focuses on Colon Carcinoma Metastatic in the Liver, Metastatic Melanoma, Metastatic Pancreatic Adenocarcinoma based on our analysis of their pipeline programs and drug development activities.